Article info

Download PDFPDF
Original research
Decreased risk of treatment failure with vedolizumab and thiopurines combined compared with vedolizumab monotherapy in Crohn’s disease

Authors

  • Julien Kirchgesner Gastroenterology, AP-HP, Hôpital Saint-Antoine, Paris, France Sorbonne Université, INSERM, Institut Pierre Louis d’Epidémiologie et de Santé Publique, Paris, France Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA PubMed articlesGoogle scholar articles
  • Rishi J Desai Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA PubMed articlesGoogle scholar articles
  • Maria C Schneeweiss Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA PubMed articlesGoogle scholar articles
  • Laurent Beaugerie Gastroenterology, AP-HP, Hôpital Saint-Antoine, Paris, France Sorbonne Université, INSERM, Institut Pierre Louis d’Epidémiologie et de Santé Publique, Paris, France PubMed articlesGoogle scholar articles
  • Sebastian Schneeweiss Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA PubMed articlesGoogle scholar articles
  • Seoyoung C Kim Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA Division of Rheumatology, Inflammation and Immunity, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA PubMed articlesGoogle scholar articles
  1. Correspondence to Mr Julien Kirchgesner, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital Department of Medicine, Boston, Massachusetts, USA; julien.kirchgesner{at}gmx.com
View Full Text

Citation

Kirchgesner J, Desai RJ, Schneeweiss MC, et al
Decreased risk of treatment failure with vedolizumab and thiopurines combined compared with vedolizumab monotherapy in Crohn’s disease

Publication history

  • Received January 19, 2022
  • Accepted March 27, 2022
  • First published April 6, 2022.
Online issue publication 
August 11, 2022

Article Versions

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.